Accessible and Affordable Moisturizers for Atopic Eczema

NCT ID: NCT02084472

Last Updated: 2014-03-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

120 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-02-28

Study Completion Date

2013-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Aqueous (EUA) cream, cetomacrogol (CMG) and emulsifying ointment (HEB) are in South Africa's essential drug list (EDL) but are not available to most rural patients. To assess whether accessible moisturizers can be used as alternatives in atopic eczema (AD), a randomized controlled trial of patients with mild-to-moderate AD, aged 1-12 years was conducted. Two separate sub-studies were conducted using a randomized controlled single (assessor) blind trial design. Study 1 compared UEA vs. liquid paraffin (unscented baby oil) for baths, all patients used HEB as moisturiser. In Study 2, 4 moisturisers were compared -HEB, CMG, petroleum jelly and petroleum jelly/Glycerine (2:1). Assessments (SCORAD, POEM, NESS and IQDOL) carried out at baseline, week 4, 8 and 12. Routine topical steroids and antihistamines were continued as prescribed.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Childhood Atopic Dermatitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Blinding Strategy

SINGLE

Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

study 1: aqueous cream and baby oil

enrolled patients in this arm use either aqueous cream or baby oil as a soap substitute

Group Type ACTIVE_COMPARATOR

Baby oil

Intervention Type OTHER

patient in study 1, arm B washed unscented liquid paraffin (baby oil) in place of aqueous cream

study 2: emulsifying ointment and cetomacrogol

patients in this study arm continue to use emulsifying ointment and cetomacrogol as a moisturiser, the current standard of care in our institution

Group Type ACTIVE_COMPARATOR

petroleum jelly

Intervention Type OTHER

patients in this arm, use petroleum jelly (vaseline), replacing emulsifying ointment as a moisturiser

Glycerine:petroleum jelly 2:1

Intervention Type OTHER

patients in this arm use glycerine and petroleum jelly mixed at a ratio of 2:1 in place of cetomacrogol as a moisturiser

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Baby oil

patient in study 1, arm B washed unscented liquid paraffin (baby oil) in place of aqueous cream

Intervention Type OTHER

petroleum jelly

patients in this arm, use petroleum jelly (vaseline), replacing emulsifying ointment as a moisturiser

Intervention Type OTHER

Glycerine:petroleum jelly 2:1

patients in this arm use glycerine and petroleum jelly mixed at a ratio of 2:1 in place of cetomacrogol as a moisturiser

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

unscented liquid paraffin

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with Atopic dermatitis as defined by the united kingdom (UK) Working party Diagnostic Criteria
* Atopic Dermatitis patient with mild to moderate stable atopic eczema with parents/guardians willing and able to apply study moisturizers as directed and commit to attend all visits.

Exclusion Criteria

* Less than 1 year of age
* Patients with atopic dermatitis treated with systemic preparations
Minimum Eligible Age

6 Months

Maximum Eligible Age

12 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Red Cross War Memorial Childrens Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Dr Carol Hlela

Dermatologist

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Nonhlanhla Khumalo, MD, PhD

Role: STUDY_DIRECTOR

University of Cape Town

Carol Hlela, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Red Cross War Memorial Children's Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Red Cross War Memorial Children's Hospital

Cape Town, Western Cape, South Africa

Site Status

Countries

Review the countries where the study has at least one active or historical site.

South Africa

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

146/2013

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Moisturizer to Prevent Atopic Dermatitis
NCT03808532 WITHDRAWN PHASE2